Aerovance lands $60M in VC
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Aerovance
|
$60M
|
Clarus Ventures |
The funding will be used to get the company's two lead products through proof-of-concept studies. |
|
Nanosphere
|
$57M
|
Bain Capital |
The capital will be used to commercialize a new and more efficient method for gene and protein testing. |
|
MacroGenics
|
$45M
|
Ventures West |
MacroGenics' lead product is slated for a Phase II/III trial to begin later this year for Type 1 diabetes. The company also has earlier-stage prospects for cancer and autoimmune diseases. |
|
Avidia
|
$43.8M
|
Skyline Ventures |
Much of the money will go to fund studies of an inhibitor of interleukin 6 for the treatment of inflammation and autoimmune disease and an inhibitor of IgE. |
|
Viron Therapeutics
|
$20M
|
Canadian Medical Discoveries Fund |
The funds will finance the company's operations through to the end of 2008. |
|
Onyvax
|
$14.7M
|
3i and SR One |
The funds raised will be used to advance the development of Onyvax-P, the firm's lead product for the treatment of prostate cancer. |
|
D-Pharm
|
$10M
|
Clal Biotechnology Industries, Israel Healthcare Ventures and Pitango Venture Capital |
D-Pharm is currently in Phase IIb with an experimental drug for strokes and is also developing therapies for brain disorders and epilepsy. |